Antisense molecules: A new class of drugs
Antisense molecules: A new class of drugs
复制标题
DOI：
10.1016/j.jaci.2015.12.1344
复制
发表时间：
2016-05-01
影响因子：
14.2
通讯作者：
Renz, Harald
中科院分区：
文献类型：
--
作者：
Potaczek, Daniel P.;Garn, Holger;Renz, Harald
对疾病发病机制的更好理解导致新的治疗靶点的鉴定。从药理学的角度来看，这些可以通过小化合物、所谓的生物制品（例如mAb和重组蛋白）或基于反义概念的一类相当新的分子来解决。最近，一个新的浪潮，探索反义策略的临床研究正在发展。除了癌症，它们主要包括感染性和非感染性疾病的试验，如慢性炎症和代谢性疾病。本文基于系统的PubMed文献检索，重点介绍了这一新兴领域的最新进展。
An improved understanding of disease pathogenesis leads to identification of novel therapeutic targets. From a pharmacologic point of view, these can be addressed by small chemical compounds, so-called biologicals (eg, mAbs and recombinant proteins), or by a rather new class of molecule based on the antisense concept. Recently, a new wave of clinical studies exploring antisense strategies is evolving. In addition to cancer, they include predominantly trials on infectious and noninfectious diseases, such as chronic inflammatory and metabolic conditions. This article, based on a systematic PubMed literature search, highlights recent developments in this emerging field.